Pacira BioSciences Inc (NASDAQ: PCRX) has experienced a rise in its stock price by 0.45 compared to its previous closing price of 24.34. However, the company has seen a fall of -8.56% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-08 that NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ:PCRA). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/PCRX.
Is It Worth Investing in Pacira BioSciences Inc (NASDAQ: PCRX) Right Now?
The 36-month beta value for PCRX is at 0.51. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for PCRX is 44.31M, and currently, shorts hold a 13.17% of that float. The average trading volume for PCRX on June 13, 2025 was 894.72K shares.
PCRX’s Market Performance
PCRX stock saw an increase of -8.56% in the past week, with a monthly gain of 4.49% and a quarterly increase of 7.76%. The volatility ratio for the week is 1.31%, and the volatility levels for the last 30 days are 1.92% for Pacira BioSciences Inc (PCRX). The simple moving average for the past 20 days is -5.39% for PCRX’s stock, with a 16.04% simple moving average for the past 200 days.
Analysts’ Opinion of PCRX
Many brokerage firms have already submitted their reports for PCRX stocks, with Truist repeating the rating for PCRX by listing it as a “Hold.” The predicted price for PCRX in the upcoming period, according to Truist is $25 based on the research report published on January 30, 2025 of the current year 2025.
Truist, on the other hand, stated in their research note that they expect to see PCRX reach a price target of $8, previously predicting the price at $30. The rating they have provided for PCRX stocks is “Sell” according to the report published on August 13th, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to PCRX, setting the target price at $14 in the report published on August 12th of the previous year.
PCRX Trading at -3.97% from the 50-Day Moving Average
After a stumble in the market that brought PCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.36% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCRX starting from RIKER LAUREN, who sale 5,578 shares at the price of $26.21 back on Jun 04 ’25. After this action, RIKER LAUREN now owns 59,564 shares of Pacira BioSciences Inc, valued at $146,208 using the latest closing price.
WILLIAMS KRISTEN, the Chief Administrative Officer of Pacira BioSciences Inc, sale 14,376 shares at $26.24 during a trade that took place back on Jun 04 ’25, which means that WILLIAMS KRISTEN is holding 161,574 shares at $377,226 based on the most recent closing price.
Stock Fundamentals for PCRX
Current profitability levels for the company are sitting at:
- -0.12 for the present operating margin
- 0.74 for the gross margin
The net margin for Pacira BioSciences Inc stands at -0.15. The total capital return value is set at -0.06. Equity return is now at value -12.27, with -6.54 for asset returns.
Based on Pacira BioSciences Inc (PCRX), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.28. The debt to equity ratio resting at 0.8. The interest coverage ratio of the stock is -5.32.
Currently, EBITDA for the company is 32.25 million with net debt to EBITDA at 17.52. When we switch over and look at the enterprise to sales, we see a ratio of 2.11. The receivables turnover for the company is 6.71for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.41.
Conclusion
In conclusion, Pacira BioSciences Inc (PCRX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
